BioCryst Expands into Rare Swelling Disease with Astria Deal
BioCryst has made a significant move into the rare swelling disease market with a deal valuing its stock at $700 million, acquiring a long-acting injectable for hereditary angioedema.
The disease, although rare, has become a highly competitive area of research, with multiple marketed medicines available to prevent or treat symptoms of potentially life-threatening swelling attacks.
BioCryst is already familiar with hereditary angioedema, with its business currently centered around Orladeyo, a once-daily pill used to prevent swelling attacks, generating $438 million in revenue last year, with expected net revenue of up to $600 million in 2025.
- Orladeyo is a once-daily pill for hereditary angioedema.
- The drug generated $438 million in revenue last year.
- Expected net revenue: up to $600 million in 2025.
Hereditary angioedema has become a very competitive area of drug research.
Author's summary: BioCryst expands into hereditary angioedema with Astria deal.
More News
- [Odds on Lando Norris winning SPOTY 2026 tumble as F1 world champion battles Luke Littler and Rory McIlroy for BBC award]
- Winona Ryder Reveals the Tragic Inspiration Behind Her “Little Women” Role and How She Tapped Into It for “Stranger Things”
- Tom & Luke Low Carb Snackaballs recall
- Babar Azam, Mohammad Rizwan in focus: PCB clears Big Bash NOCs for Pakistan players
- DansLesCoulisses.com | Pour en savoir plus que les autres!
- Ryder Tully Instagram Bio Summary
- Sydney Sixers Vs Adelaide Strikers, WBBL 2025: SYS-W Beat AS-W By One Run Thanks To Ellyse Perry Century
- Women's Big Bash League: Brisbane Heat's Winless Season Ends With 7-Wicket Loss Against Perth Scorchers
- Katy Perry en couple avec Justine Trudeau : l’ex-Premier ministre la regarde
- [Luke Skywalker - Wikipedia summary]